GlassScriptPhysician profile
Tyler Stanfield
NPI 1780243915
$1,139.59
in general payments reported to CMS, 2019-2025
15 companies · $666 in 2025
The $666 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.30 · 2022: $71.61 · 2023: $95.08 · 2024: $278 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.17 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $196.17 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $49.51 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.57 | 2025 | Caplyta |
| Pfizer INC. | $46.49 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $44.11 | 2024-2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Tris Pharma INC | $24.34 | 2025 | Onyda Xr |
| Lundbeck LLC | $19.81 | 2025 | Rexulti |
| Lilly USA, LLC | $16.25 | 2024 | Zepbound |
| Amgen INC. | $15.58 | 2025 | Repatha, Otezla |
| Exact Sciences Corporation | $14.31 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Stanfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.